Skip to main content
ConductScienceScienceDex

Marcus Aaron Horwitz

NIH Rank #7157
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 1865892Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Internal Medicine

NIH Funding · FY2025

Linked Award Amount
$1.9M
Full award amounts, FY2025
Award Records
3
Records listing this PI
Award-Linked Rank
#7,157
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Marcus Aaron Horwitz. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2025 award records by amount

NIH award records listing Marcus Aaron Horwitz as a PI. Multi-PI records show the full award amount for context.

  • 5R01AI183978-02R01
    Efficacy and Safety of AI-enabled PRS Regimen VI (Clofazimine, Bedaquiline and Pyrazinamide) as Ultra-Short Course Therapy of LTBI in Non-Human Primates in a setting mimicking HIV co-infection
    University of California, Los Angeles
    $931.8K
    award amount
  • 5R01AI148122-05R01
    Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance
    University of California, Los Angeles
    $756.6K
    award amount
  • 1R21AI185484-01A1R21
    Identification by High Throughput Screening of Inhibitors of the Mycobacterium tuberculosis ESX-1 and ESX-5 Type VII Secretion Systems – critical virulence determinants and novel drug targets
    University of California, Los Angeles
    $236.3K
    award amount

Award organization

Organizations that administered FY2025 awards listing Marcus Aaron Horwitz as a PI.

FY2025 award administered by University of California, Los Angeles (CA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    University of California, Los Angeles
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    $2M Cumulative Funding
  5. 2024
    Entered Top 50% Nationally
    Ranked #4322
  6. 2024
    Entered Top 25% Nationally
    Ranked #4322
  7. 2025
    R01 Grant Holder
  8. 2026
    $5M Cumulative Funding

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Marcus Aaron Horwitz.

Deepak Kaushal
University of California, Los Angeles
3
shared awards
Z Hong Zhou
University of California, Los Angeles
1
shared award

Explore further

Find collaborators for Marcus Aaron Horwitz

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →